Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Oak vs Omada Health

Oak
Graded #42

Higher grade

vs+20.300000000000004
Omada Health
Graded #435

Lower grade

The verdict

Oak takes it — 75.9/100 to 55.6/100.

Oak grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The cheapest published prices on the board, sold as a package with no membership fee.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOak +51
96
45
Dose & formulationOak +22
62
40
Clinical oversightOmada Health +11
66
77
Labs & monitoringOmada Health +3
58
61
FulfillmentOak +26
88
62
Contract termsOak +33
88
55
Oak · left barOmada Health · right bar

The numbers

MetricOakOmada Health
WeighScore75.9/10055.6/100
GradeCC
Scorecard rank#42#435
SemaglutideFrom $119/moNot disclosed
TirzepatideFrom $185/moNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Oak

Graded #42 · C

Strengths

  • Lowest published prices here — semaglutide from $119/mo, tirzepatide from $185/mo
  • One price across every dosage, so titrating up costs no more
  • No membership or subscription fee, and free shipping
  • All 50 states, offered in Spanish as well as English

Where it loses points

  • Same-day approval with no video call means very little clinical contact before a prescription
  • No published lab or monitoring programme
  • Injection only, and no brand-name lane
  • Sold as packages, so re-ordering is on you
Omada Health

Graded #435 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard